@shareman In your reply to my post you note
The question is not why IMU's price has fallen so heavily.
The real question is why did the share price get so inflated in the first place.
You may not be aware having not followed my research, the reasons for the stock rising to 60 cents were given by me in late 2022. That question has already been answered by myself and is well known to LTH’s of IMU. For your reference the reasons for the rise were provided by me in late 2022 can be found herein, when I wrote :
1. Imugene is developing safe drugs and vaccines for cancer patients
2. Imugene’s drugs have exhibited low levels of toxicity in clinical trials
3. Imugene’s drugs have shown to cause limited if any side effects in clinical trials
4. Imugene has the technology to map, image and track oncolytic virus (OV) treatment in patients
5. Pre clinical trials have been outstanding across all of Imugene’s 3 immunotherapy platforms
6. Imugene’s B cell clinical trials have produced efficacy in both phases 1 and 2
7. Imugene’s oncarlytics platform has the ability to target solid tumours the “holy grail” of cancer
8. Imugene’s personnel are experienced pre and post clinical professionals
9. Imugene has no debt and over 100 million AUD in the bank for future programs and trials
10. Imugene has licensed multiple B cell vaccines from world leading innovators and institutes
11. Pre-clinically CF 33, the powerful OV was successful in eradicating 90% of cancer lines pre - clinically
12. Imugene's vaccines have patent lives out to 2036, 7 and 8 providing long shelf lives
13. Imugene has strategically secured patent protection in South East Asia, the US and Europe
14. Her Vaxx has prolonged lives & reduced death rates in Phase 2 trials over the standard of care
15. 3 Big pharma including Merck & Pfizer are participating in combination trials with Her Vaxx
16. PD1 Vaxx has eliminated cancer in patient(s) in Phase 1 clinical trials
17. Imugene’s B cell treatments have preclinically been successful in combination with eachother
18. The immunotherapy and OV markets are forecast to grow at double digit CAGR’s in the 2020’s
19. Imugene inventors Yuman Fong and Professor Kaumaya are world renowned
20. Imugene presented their drugs and treatments in the worlds leading cancer forums in 2021
21. The existing directors all hold more shares on the IMU register than they did 12 months ago
22. Imugene has secured ongoing R&D grants and returns from the Australian Government
23. Imugene’s Chairman was recently awarded biotech Chairman of the year in Australia
24. Imugene has recently attracted leading clinical practitioners to their organisation
25. Imugene has 4 US FDA approvals in the USA to trial their drugs in patients
26. Comparable drugs to IMU’s yield revenues of up to 16bn USD per annum, i.e., Keytruda
27. Imugene has had no significant setbacks in phase one and two clinical trials in 2020/2021
28. Imugene’s oncarlytics platform has secured two collaborations with leading US Biotech firms
29. IMU’s immunotherapy drugs are less expensive to produce & administer than existing drugs
30. Building up one’s immunity has the potential to treat illnesses other than just cancer
31. IMU drugs are in favour with US regulators due to their comparatively lower retail price
32. Immunotherapy drugs worldwide are being fast tracked into production by big Pharma
33. In 2022 Imugene shall potentially secure another 3 FDA IND approvals in the US
34. Imugene has already performed capital raises and has no plans for further ones in 2022/23
35. IMU has 3 product platforms a long product pipeline and potentially multiple revenue streams
36. From a technical perspective Imugene is well off year highs
37. Leading analysts @ Roth Capital & Bell Potter have buys on IMU & price targets up to 71 cents
38. Imugene has money in its budget to commence manufacturing facilities for their products
39. IMU’s CEO Leslie Chong has decades of scientific & technical experience @ RocheGenentech
40. IMU is an ethical investment providing safe @ effective treatment for cancer patients globally
41. Imugene staff work tirelessly to secure favourable outcomes for cancer patients worldwide
42. CF33, oncarlytics, Eureka & Celularity collaborations could eradicate solid tumours in patients
43. Imugene is constantly searching for new combination drugs and partners to combine with
44. Leading US fund managers Vanguard, Blackrock @ State Street are leading IMU shareholders
45. Imugene is in ongoing discussions with several interested parties in their oncarlytics platform
46. Her Vaxx founder Ursula Wiederman @ the team at University of Vienna are world renowned
47. Leading US cancer universities & clinics Mayo Clinic & City of Hope are Imugene associates
48. Imugene is gazetted to present again this year in leading cancer forums the AACR @ ESMO
49. HerVaxx & PD1Vaxx could realise license, takeover/commercial partnerships as early as 2022/3
50. Big pharma Roche recently announced plans to combine with PD1 Vaxx in a clinical trial
With all due respect the opinion you have presented in reply to my post is fallacious, fictitious and to be quite honest erroneous. You stated :
In my view, the pumping of the IMU share price was, at least in part, due to many gullible and vulnerable people falling for the hype that was generated by pumpers/promoters across social media and stock forums that IMU was highly likely to succeed in curing cancer.
For the record, stocks rise based purely on increased levels of demand over supply. Contrary to your negligible assumptions above, the original uptick in IMU’s share price took place when Jack Mann of Mann Beef invested, when the stock subsequently rise into the low two’s. And thereafter having seen the stock fall slightly, when he reinvested. His investments were based on the advice of two LTH’s who held approximately 83m IMU shares at the time. LTH’s who had been invested in the stock for over 5 years at that stage, who were acutely aware of the company’s staff, IP and future development plans. He is neither a gullible or vulnerable person. Mann was driven to invest in the Imugene innovators and their drive to continue both prodigious and successful work in the fight against cancer. Jack Mann is busy managing and owns a number of cattle enterprises in Northern QLD, to the best of my knowledge he has little or no time for social media.
Secondly having had meetings with Imugene staff and a number of leading stakeholders a collective of small cap funds in Australia made the decision to invest in the stock. Whilst they later had to sell stock when the IMU share price reached a market cap that was above their existing small cap mandates, they had over time pushed the stock into the low teens in price, given their consistent demand for the stock. To assume they made their investment decisions based on social media, pumpers and promoters is a nonsense.
Thirdly when Alex Waislitz of Thorney Investments made the decision to purchase and back IMU many people followed. Thorney specialises in emerging companies across a broad range of industries including manufacturing, technology, mining services and resources and has been successful in doing so. Thorney Opportunities is an ASX listed company, and Waislitz has been a director of one of Australia's leading public companies Visy Industries. To assume he is a gullible and vulnerable person is preposterous.
Fourthly when the world leading fund managers Blackrock, Vanguard Investments and State Street came on board as cornerstone investors in IMU other fund managers and investors understood that these investors were leading shareholders of Merck who would have performed their own necessary due diligence, and would have only committed if they were confident in the IMU fundamentals at the time. It goes without saying Vanguard has continued to strengthen their holding in IMU, and once again to assume they base their decisions on social media, stock threads, pumpers and promoters is verging on the laughable.
Finally on the supply and demand front the acquisition which drove IMU well into the black, propelling the stock toward 60 cents was that made by JP Morgan Hong Kong for their clients in late 2022. With close to 100s of million of shares in IMU changing hands in a matter of days the stock drove through the 40 and 50 cent barriers north. JP Morgan employ an experienced team of healthcare analysts worldwide and once again to assume they base their investments decisions based upon hype over social media and stock forums is hysterical to say the least.
You note in your reply to me In reality, this is a highly speculative stock.
The reality of the situation is that IMU is no longer a speculative stock. The pre and now post clinical results of their B cell and OV platforms have significantly de-risked the stock and taken away a substantial amount of risk for early stage investors.
And in answer to your persistent drivel as to why (unlike you), people would care to invest in Imugene the answer is simple. They believe in world leading innovator’s such as Ursula Wiedermann, Pravin Kaumaya and Yuman Fong. Why these individuals have resumes longer than your posts. They have achieved remarkable success in the clinic. CF33 wiped out over 90 percent of cancer lines and this is fact, not fiction. Investors follow successful individuals. And when it come to successful individuals, Imugene have them in spades. That is why leading Big Pharma's choose to partner with IMU, unlike the one hit wonder cancer success stories you feed us in your links. Imugene is a broad based, multi dimensional immunotherapy company with cash in the bank stepping closer and closer to bringing cost effective, safe and efficacious drugs to much needy cancer patients. Having done so the so called gullible and vulnerable people you speak of are sure to be the first to run to social media to tell their stories. Cancer patients who have benefitted from Imugene’s drugs may just beat them to the keyboard. I say good luck to them.
DYOR - seek investment advice where necessary - opinions only
(20min delay)